Taisho Pharmaceutical saw the highest growth of 99% in patent filings in December and 99% in grants in November in Q4 2023. Compared to Q3 2023, Q4 2023 saw no growth in patent filings and grants by 66%. GlobalData’s DataBook provides a comprehensive analysis of Taisho Pharmaceutical’s patent filings and grants. Buy the databook here.
Taisho Pharmaceutical has been focused on protecting inventions in Japan(JP) with 12 publications in Q4 2023
The Japan(JP) Patent Office dominates the patent filings and grants with nearly 91% filings and 50% grants. The Japan(JP), World Intellectual Property Organization(WIPO), South Africa(ZA), and European Patent Office(EPO) patent Office are among the top ten patent offices where Taisho Pharmaceutical is filings its patents. Among the top granted patent authorities, Taisho Pharmaceutical has 50% of its grants in Japan(JP) and 50% in South Africa(ZA).
Patents related to health & wellness and meat & seafood alternatives lead Taisho Pharmaceutical's portfolio
Taisho Pharmaceutical has the highest number of patents in health & wellness followed by, meat & seafood alternatives and rare diseases. For health & wellness, nearly 38% of patents were filed and no patents were granted in Q4 2023.
For comprehensive analysis of Taisho Pharmaceutical's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.